Pfizer Signs Up Seven New York Institutions To Create Biomedical Discovery Engine
This article was originally published in The Pink Sheet Daily
Executive Summary
New York deals follow UCSF tie-up in San Francisco; six more city-based alliances are to come.
You may also be interested in...
Sanofi Reworks R&D To Tackle Risk, Meet Unmet Need
A newly launched grass roots campaign aimed at academics and the biotech community offers some insight into Sanofi's reinvigorated R&D organization, which is meant to be more flexible and entrepreneurial. Despite the potential upheaval caused by its recent $20.1 billion acquisition of Genzyme, Sanofi is talking up a handful of targeted areas of high unmet need and commensurately huge opportunities that are a critical part of its long-range strategy.
Sanofi Reworks R&D To Tackle Risk, Meet Unmet Need
A newly launched grass roots campaign aimed at academics and the biotech community offers some insight into Sanofi's reinvigorated R&D organization, which is meant to be more flexible and entrepreneurial. Despite the potential upheaval caused by its recent $20.1 billion acquisition of Genzyme, Sanofi is talking up a handful of targeted areas of high unmet need and commensurately huge opportunities that are a critical part of its long-range strategy.
Gilead Joins Up With Yale In Cancer Discovery Collaboration
The biotech has partnered with Yale University on cancer research in a deal that could provide $100 million in funding to Yale over 10 years.